Krystal Biotech Analyst Lifts Price Target More Than 50% On Positive Phase 2 Data, RMAT DesignationBenzinga • 06/25/19
Krystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDAMarket Watch • 06/24/19